Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune cell interplay in colorectal cancer prognosis.

Literature DB >> 26483876

Immune cell interplay in colorectal cancer prognosis.

Samuel E Norton¹, Kirsten A Ward-Hartstonge¹, Edward S Taylor¹, Roslyn A Kemp¹.

Abstract

The immune response to colorectal cancer has proven to be a reliable measure of patient outcome in several studies. However, the complexity of the immune response in this disease is not well understood, particularly the interactions between tumour-associated cells and cells of the innate and adaptive immune system. This review will discuss the relationship between cancer associated fibroblasts and macrophages, as well as between macrophages and T cells, and demonstrate how each population may support or prevent tumour growth in a different immune environment.

Entities: Disease Species

Keywords: Colorectal cancer neoplasms; Fibroblasts; Immune system processes; Macrophages; T lymphocytes

Year: 2015 PMID： 26483876 PMCID： PMC4606176 DOI： 10.4251/wjgo.v7.i10.221

Source DB: PubMed Journal: World J Gastrointest Oncol

105 in total

Review 1. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors: Subhra K Biswas; Alberto Mantovani
Journal: Nat Immunol Date: 2010-09-20 Impact factor: 25.606

2. Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors: Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal: N Engl J Med Date: 2005-12-22 Impact factor: 91.245

3. Low expression of Granzyme B in colorectal cancer is associated with signs of early metastastic invasion.

Authors: Paul Salama; Michael Phillips; Cameron Platell; Barry Iacopetta
Journal: Histopathology Date: 2011-08 Impact factor: 5.087

4. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses.

Authors: Thomas Krausgruber; Katrina Blazek; Tim Smallie; Saba Alzabin; Helen Lockstone; Natasha Sahgal; Tracy Hussell; Marc Feldmann; Irina A Udalova
Journal: Nat Immunol Date: 2011-01-16 Impact factor: 25.606

5. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs.

Authors: Andrew T Chan; Shuji Ogino; Edward L Giovannucci; Charles S Fuchs
Journal: Gastroenterology Date: 2010-11-27 Impact factor: 22.682

6. Intestinal inflammation targets cancer-inducing activity of the microbiota.

Authors: Janelle C Arthur; Ernesto Perez-Chanona; Marcus Mühlbauer; Sarah Tomkovich; Joshua M Uronis; Ting-Jia Fan; Barry J Campbell; Turki Abujamel; Belgin Dogan; Arlin B Rogers; Jonathan M Rhodes; Alain Stintzi; Kenneth W Simpson; Jonathan J Hansen; Temitope O Keku; Anthony A Fodor; Christian Jobin
Journal: Science Date: 2012-08-16 Impact factor: 47.728

Review 7. The plasticity of human Treg and Th17 cells and its role in autoimmunity.

Authors: Markus Kleinewietfeld; David A Hafler
Journal: Semin Immunol Date: 2013-11-05 Impact factor: 11.130

8. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer.

Authors: Mona Karlsson; Per Marits; Kjell Dahl; Tobias Dagöö; Sven Enerbäck; Magnus Thörn; Ola Winqvist
Journal: Ann Surg Oncol Date: 2010-01-30 Impact factor: 5.344

9. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature.

Authors: Qiong-wen Zhang; Lei Liu; Chang-yang Gong; Hua-shan Shi; Yun-hui Zeng; Xiao-ze Wang; Yu-wei Zhao; Yu-quan Wei
Journal: PLoS One Date: 2012-12-28 Impact factor: 3.240

Review 10. Fibroblast heterogeneity in the cancer wound.

Authors: Daniel Öhlund; Ela Elyada; David Tuveson
Journal: J Exp Med Date: 2014-07-28 Impact factor: 14.307

11 in total

1. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome.

Authors: Marwan Fakih; Ching Ouyang; Chongkai Wang; Travis Yiwey Tu; Maricel C Gozo; May Cho; Marvin Sy; Jeffrey A Longmate; Peter P Lee
Journal: J Clin Invest Date: 2019-10-01 Impact factor: 14.808

2. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

Authors: Bert H O'Neil; John M Wallmark; David Lorente; Elena Elez; Judith Raimbourg; Carlos Gomez-Roca; Samuel Ejadi; Sarina A Piha-Paul; Mark N Stein; Albiruni R Abdul Razak; Katia Dotti; Armando Santoro; Roger B Cohen; Marlena Gould; Sanatan Saraf; Karen Stein; Sae-Won Han
Journal: PLoS One Date: 2017-12-28 Impact factor: 3.240

9. Differential gene expression of tumor-infiltrating CD33⁺ myeloid cells in advanced- versus early-stage colorectal cancer.

Authors: Salman M Toor; Rowaida Z Taha; Varun Sasidharan Nair; Reem Saleh; Khaled Murshed; Mohamed Abu Nada; Eyad Elkord
Journal: Cancer Immunol Immunother Date: 2020-09-30 Impact factor: 6.968

Review 10. Curcumin and colorectal cancer: An update and current perspective on this natural medicine.

Authors: Wenhao Weng; Ajay Goel
Journal: Semin Cancer Biol Date: 2020-02-20 Impact factor: 15.707